Market research

Drug Delivery Market 2026

Explore licensesfrom $3,939

Assess the study’s coverageRead the public overview, then compare the chapter outline with your research brief.

12report chapters

Public research overviewHow we research Research team

Drug Delivery: Formats, Platforms and Access

Drug Delivery is examined here as the commercial ecosystem of dosage forms, delivery technologies, drug-device combinations, components and supporting services—not as a synonym for all pharmaceutical sales. Inspected offerings span oral therapies, injectable presentations, nasal and pulmonary systems, ophthalmic and dermal delivery, and transdermal combination products. These are distinct commercial categories rather than interchangeable technologies.

Aptar's portfolio illustrates the delivery-system and component supplier role, while Catalent describes a CDMO role supporting development, launch and lifecycle supply. The analysis therefore separates technology and service suppliers from finished-product sponsors, purchasing healthcare organizations and payers.

The central business question is which offering can secure product-specific access and a sustainable buyer relationship. Availability, distribution and funding must be assessed separately: Insulet's Canadian access information, for example, distinguishes product sale, provincial reimbursement, private insurance and distribution partners. Our synthesis is that commercial differentiation depends on the delivery format and the route to funded, supportable access—not novelty alone.

Sources and supporting claims 5

360iResearch introduction

Inside the research

Coverage at a glance

Selected branches from the published table of contents. Follow a chapter to see every subchapter in context.

  1. Chapter 7 Region

    • Asia-Pacific
    • North America
    • Latin America
    • Europe
    More in this chapter
  2. Chapter 8 Group

    • ASEAN
    • GCC
    • European Union
    • BRICS
    More in this chapter
  3. Chapter 9 Country

    • United States
    • Canada
    • Mexico
    • Brazil
    More in this chapter

Licensing, Ownership and Service Expansion in Drug Delivery

Delivery rights and product authorization are distinct competitive milestones. On February 22, 2024, Alteogen announced an amended exclusive agreement granting MSD worldwide rights to use ALT-B4 recombinant human hyaluronidase for subcutaneous pembrolizumab. In September 2025, the FDA authorized Keytruda Qlex for specified subcutaneous solid-tumor indications. These records illustrate the commercial importance of route-specific rights and authorization; neither licensing nor approval alone measures adoption.

Ownership changes require a fresh counterparty assessment. Novo Holdings completed its acquisition of Catalent on December 18, 2024, moving the CDMO into private ownership. This was a completed ownership event, not merely a proposed transaction. The completion notice does not establish subsequent customer-service effects, integration outcomes or additional accessible capacity. Buyers should therefore distinguish the changed ownership fact from assumptions about supply continuity.

Device vendors are extending the surrounding service proposition. Insulet's February 2026 Middle East announcement paired Omnipod 5 availability with the introduction of Omnipod Discover, a data-management platform. Our interpretation is that competition can extend beyond the device to the associated information relationship. The launch does not itself demonstrate stronger retention, improved commercial economics or AI capability.

Sources and supporting claims 4

AI in Drug Delivery: Internal Adoption Before Proven Commercial Returns

The inspected evidence is clearer on internal information work than on demonstrated market-wide commercial benefits. In August 2026, Ypsomed reported an initial rollout of YpsoMind, its in-house AI solution. It separately described reporting initiatives connecting business systems to compare portfolio plans with completed project work. These disclosures support organizational adoption, not a quantified effect on drug-delivery revenue or customer retention.

West's September 2026 recruitment notice sought a business-facing AI leader coordinating with supply chain, commercial, finance and other functions. This indicates capability building and intended organizational reach; a vacancy is not evidence of a completed deployment or realized return.

Vendor offerings also require careful classification. Insulet markets Omnipod Discover as an analytics and reporting platform, but the inspected launch record does not establish generative-AI functionality. Our synthesis is that AI could reduce information friction in commercial and service work. Market-specific customer-service adoption, cumulative savings and broader competitive benefits remain unestablished by these sources.

Sources and supporting claims 3

Regional Drug Delivery Opportunities Depend on Access Channels

North America: Product authorization and funded access are different gates. The United States evidence concerns a specific subcutaneous oncology authorization, while Canadian pump coverage is province-specific. Our commercial implication is to separate the regulatory launch plan from the payer and distribution plan rather than assume a regional access model.

Latin America: The strongest inspected channel evidence is from Brazil, where central procurement of human insulin presentations and pen needles feeds subnational distribution. This makes tender participation and fulfilment relationships relevant commercial questions. The Brazilian arrangement should not be generalized to other Latin American markets that were not inspected to comparable depth.

Europe: The European Union's combination-product framework connects medicinal-product authorization with applicable device-conformity requirements. Commercial readiness therefore concerns both parts of the offering. That framework is not used here as a proxy for every market in Europe.

Middle East: Insulet announced Omnipod 5 commercial availability in Saudi Arabia, Kuwait, Qatar and the United Arab Emirates in February 2026. This supports a concrete vendor-entry finding, but not uniform public coverage or region-wide availability.

Africa: The Global Fund's September 2026 update reports lenacapavir shipments reaching Eswatini and Zambia in November 2025, followed by introductions in additional African countries. Our interpretation is that financing, procurement and introduction partnerships create accessible channels for long-acting delivery. The record does not establish continent-wide access.

Asia-Pacific: Company launch records document oral semaglutide in China, Mounjaro KwikPen in India and Omnipod 5 in Australia. Together they support parallel opportunities across oral, injectable and pump formats—not a demonstrated regional preference for one delivery route.

Sources and supporting claims 9

Drug Delivery Across Policy and Procurement Groupings

ASEAN. The legal-instrument catalogue lists the 2014 ASEAN Agreement on Medical Device Directive as subject to national ratification or acceptance. The retrieved record does not resolve current product-specific implementation or supplier access. No ASEAN-wide registration advantage is assumed in the commercial assessment.

European Union. A concrete access condition is Article 117, applicable since May 26, 2021. Relevant integral drug-device combinations require device-conformity documentation alongside the medicinal-product application, with presentation and exemptions determining the requirement. This addresses authorization, not reimbursement.

BRICS and G7. The June 2025 BRICS health-minister record reports disease-elimination and vaccine-cooperation priorities, not a specific drug-delivery purchase. A common commercial authorization or pooled delivery-device procurement channel was not established here. The G7's 2025 Industry, Digital and Technology declaration emphasizes medical-countermeasure supply-chain resilience and commercialization of emerging health technologies. That provides strategic context for supply-continuity positioning, but not evidence of a funded G7-wide drug-delivery program.

GCC. The Gulf Health Council describes joint procurement of medicines, medical devices and supplies for member states and participating entities, including annual planning and supplier qualification. This is a potential institutional route for suitable delivery offerings; no specific delivery-device award or guaranteed volume was established in this review.

NATO. Retrieved text from NSPA's March 2025 Medical Support Partnership document describes consolidated medical procurement and logistics support. It identifies an institutional channel worth distinguishing from civilian healthcare markets, but does not establish a drug-delivery-device order.

Sources and supporting claims 6

Featured Drug Delivery Markets: Country Access and Commercial Roles

North America—United States, Canada and Mexico. In the United States, the September 19, 2025 FDA authorization of Keytruda Qlex establishes a route-specific oncology access milestone, not switching or sales. In Canada, Insulet states that Omnipod 5 is available for sale and lists particular provincial reimbursement markets, including Ontario and Nova Scotia; eligibility and private coverage remain separate questions. For Mexico, Novo Nordisk's February 2025 notice announced a semaglutide launch beginning in April 2025. That historical announcement does not establish current national stock or reimbursement.

Latin America—Brazil. The Ministry of Health's insulin record distinguishes central purchasing from state and municipal distribution and dispensing. A supplier's commercial proposition must therefore address both procurement eligibility and downstream channel responsibilities. Current winning suppliers and individual contract performance were not established.

Europe—Germany, France and Italy. Insulet's August 2025 presentation dates Omnipod 5 launches to August 2023 in Germany, June 2024 in France and January 2025 in Italy. These establish different launch histories, not comparative adoption. Local coverage, installed bases and purchasing economics were not established on a comparable basis, limiting conclusions about replacement versus new-account opportunities.

Europe—Spain and United Kingdom. Spain's AEMPS states that inhalers are not substitutable without express prescriber authorization. Commercial replacement assumptions therefore cannot rest on environmental positioning alone. For the United Kingdom, retrieved NHS England text describes a phased hybrid closed-loop rollout starting in April 2024. This establishes an England-specific access initiative, not uniform United Kingdom funding or completed uptake.

Europe—Russia. A retrieved Russian Chamber of Commerce origin-examination record identifies GEROPHARM's Semavic Next in a pen presentation. The examination's stated validity ended on October 27, 2025; that is not evidence that the product's registration expired. Current commercial availability, procurement outcomes and channel continuity remain unresolved.

Asia-Pacific—Australia, China and India. Insulet's May 2025 results announcement reports an Australian Omnipod 5 launch without establishing universal funding. Novo Nordisk announced the full China launch of oral semaglutide tablets on January 11, 2025. Lilly announced Mounjaro KwikPen availability across India through registered prescription pharmacies on August 12, 2025. These are different format and channel opportunities, not evidence of equivalent reimbursement or relative sales.

Asia-Pacific—Japan and South Korea. Chugai documents the Japanese launch and national health-insurance price listing of Phesgo on November 22, 2023, providing both launch and reimbursement milestones. South Korea's outward-facing licensing role is illustrated by Daejeon-based Alteogen's worldwide MSD agreement. That relationship does not establish domestic sales, local authorization or manufacturing location.

Sources and supporting claims 13

Commercial Priorities for Drug Delivery Leaders

Choose the business role before expanding the portfolio. Compare licensing a delivery-enabling platform with retaining an established presentation or controlling more of the offering. Require clarity on territorial rights, contingent payments and commercial-supply obligations. Reconsider the choice when product-specific authorization and funded demand materially change the economics; an exclusive license is not assured adoption.

Stage geographic spending against accessible demand. Separate product launch from payer eligibility and tender qualification. Canadian coverage distinctions and Gulf procurement requirements support a partnership-first alternative to immediate broad direct coverage where access remains uncertain. Expand commitments when eligible buyers, distribution responsibilities and actual orders are established.

Re-underwrite counterparties after ownership changes. The completed Catalent transaction supports reviewing legal counterparties, contractual continuity and customer commitments. It does not justify presuming disruption. Compare supplier concentration with diversification only after accounting for transition costs and existing commercial obligations.

Evaluate AI as an information-work investment. Internal AI adoption supports considering document retrieval, account-information support and service triage—not assuming proven customer-service returns. Proceed where data rights, human review and measurable administrative benefits are clear. Retain ordinary workflows when those prerequisites or benefits cannot be demonstrated.

Sources and supporting claims 5

Drug Delivery Research Scope and Evidence Limits

This qualitative review uses an October 29, 2026 research cutoff. Public source text was inspected from supplier portfolios, company announcements, investor presentations, regulatory summaries, procurement-program records and official document excerpts. Dated material includes older policy records and commercial disclosures through September 2026; historical records were not treated as evidence of today's sales.

The analysis compared ownership, licensing, authorization, launch, reimbursement and distribution as separate business facts. Chinese-, Portuguese-, Spanish- and Russian-language material was used where relevant. Company statements remain attributed disclosures, not independent confirmation of availability or commercial success.

Some originating pages could not be loaded in full. In particular, ASEAN, BRICS, NATO and Russia findings rely on limited retrieved official excerpts; their current implementation, awards or supply questions remain unresolved. Coverage illustrates commercial mechanisms rather than an exhaustive product census or comparable demand measurement across countries.

No interviews, surveys, market sizing, share estimates, numerical forecasts or statistical validation were performed. Research remained non-operational and excluded experimental methods, production instructions and treatment guidance.

Drug Delivery Outlook: Technology Plus Accessible Demand

The inspected records support coexistence rather than convergence: oral therapies, injectable presentations and device-based delivery can develop through different commercial channels. Authorization records, company launches and publicly financed introductions establish distinct milestones—not one winning route or uniform geographical demand.

The most useful milestones to watch are product-specific authorization, funded eligibility, confirmed launches, procurement awards, contractual supply continuity and disclosed nonclinical AI outcomes. Our synthesis favors selective portfolio and channel commitments, with broader expansion conditional on documented buyer access and contracted demand. Announced partnerships, approvals and launches should remain separate stages in the commercial case rather than being converted into predictions of success.

Sources and supporting claims 4

Research report

Table of contents

  1. 1.Preface
    1. 1.1Objectives of the Study
    2. 1.2Market Definition
    3. 1.3Market Segmentation & Coverage
    4. 1.4Years Considered for the Study
    5. 1.5Currency Considered for the Study
    6. 1.6Language Considered for the Study
    7. 1.7Key Stakeholders
  2. 2.Research Methodology
    1. 2.1Introduction
    2. 2.2Research Design
      1. 2.2.1Primary Research
      2. 2.2.2Secondary Research
    3. 2.3Research Framework
      1. 2.3.1Qualitative Analysis
      2. 2.3.2Quantitative Analysis
    4. 2.4Market Size Estimation
      1. 2.4.1Top-Down Approach
      2. 2.4.2Bottom-Up Approach
    5. 2.5Data Triangulation
    6. 2.6Research Outcomes
    7. 2.7Research Assumptions
    8. 2.8Research Limitations
  3. 3.Executive Summary
    1. 3.1Introduction
    2. 3.2CXO Perspective
    3. 3.3New Revenue Opportunities
    4. 3.4Next-Generation Business Models
    5. 3.5Industry Roadmap
  4. 4.Market Overview
    1. 4.1Introduction
    2. 4.2Key Growth Contribution
    3. 4.3Industry Ecosystem & Value Chain Analysis
      1. 4.3.1Supply-Side Analysis
      2. 4.3.2Demand-Side Analysis
      3. 4.3.3Stakeholder Analysis
    4. 4.4Market Dynamics
      1. 4.4.1Key Drivers
      2. 4.4.2Key Restraints
      3. 4.4.3Key Opportunities
      4. 4.4.4Key Challenges
    5. 4.5Porter’s Five Forces Analysis
    6. 4.6PESTLE Analysis
    7. 4.7Market Outlook
      1. 4.7.1Near-Term Market Outlook (0-2 Years)
      2. 4.7.2Medium-Term Market Outlook (3-5 Years)
      3. 4.7.3Long-Term Market Outlook (5-10 Years)
    8. 4.8Go-to-Market Strategy
  5. 5.Market Insights
    1. 5.1Consumer Insights & End-User Perspective
    2. 5.2Consumer Experience Benchmarking
    3. 5.3Opportunity Mapping
    4. 5.4Distribution Channel Analysis
    5. 5.5Pricing Trend Analysis
    6. 5.6Regulatory Compliance & Standards Framework
    7. 5.7ESG & Sustainability Analysis
    8. 5.8Disruption & Risk Scenarios
    9. 5.9Return on Investment & Cost-Benefit Analysis
  6. 6.Cumulative Impact of Artificial Intelligence 2026
  7. 7.Drug Delivery Market, by Region
    1. 7.1Introduction
    2. 7.2Asia-Pacific
    3. 7.3North America
    4. 7.4Latin America
    5. 7.5Europe
    6. 7.6Middle East
    7. 7.7Africa
  8. 8.Drug Delivery Market, by Group
    1. 8.1Introduction
    2. 8.2ASEAN
    3. 8.3GCC
    4. 8.4European Union
    5. 8.5BRICS
    6. 8.6G7
    7. 8.7NATO
  9. 9.Drug Delivery Market, by Country
    1. 9.1Introduction
    2. 9.2United States
    3. 9.3Canada
    4. 9.4Mexico
    5. 9.5Brazil
    6. 9.6United Kingdom
    7. 9.7Germany
    8. 9.8France
    9. 9.9Russia
    10. 9.10Italy
    11. 9.11Spain
    12. 9.12China
    13. 9.13India
    14. 9.14Japan
    15. 9.15Australia
    16. 9.16South Korea
  10. 10.Competitive Landscape
    1. 10.1Market Share Analysis, 2025
    2. 10.2Market Concentration Analysis, 2025
    3. 10.3Recent Developments & Impact Analysis, 2025
    4. 10.4Product Portfolio Analysis, 2025
    5. 10.5Benchmarking Analysis, 2025
  11. 11.Companies Covered
  12. 12.Key Experts

Loading the sample request form…